This multicenter Level-I RCT compares the InSpace biodegradable subacromial balloon spacer against arthroscopic partial repair. The population was patients ≥40 with irreparable, posterosuperior massive rotator cuff tears and an intact subscapularis after failed nonoperative care. The primary outcome was change in ASES score through 24 months.
When you face an irreparable posterosuperior massive cuff tear in a patient with an intact subscapularis and no advanced arthritis, this trial gives you a defensible alternative to partial repair.
The two options produce comparable ASES outcomes at 2 years, so the decision shifts to recovery speed and operative burden. The spacer wins on faster motion recovery and a roughly 27-minute shorter operation.
Think of the spacer mechanistically: it recenters the humeral head and offloads the acromiohumeral interface long enough to let the deltoid be retrained in a low-pain state. Because it resorbs by 12 months, durable benefit depends on the rehab it enables, not the balloon itself.
Patient selection matters. Series with low preoperative elevation and true pseudoparalysis had high failure and conversion to reverse TSA, so reserve the spacer for patients who still have functional forward elevation. Note the funding source (the device manufacturer) when weighting this evidence.
This multicenter Level-I RCT compares the InSpace biodegradable subacromial balloon spacer against arthroscopic partial repair. The population was patients ≥40 with irreparable, posterosuperior massive rotator cuff tears and an intact subscapularis after failed nonoperative care. The primary outcome was change in ASES score through 24 months.
When you face an irreparable posterosuperior massive cuff tear in a patient with an intact subscapularis and no advanced arthritis, this trial gives you a defensible alternative to partial repair.
The two options produce comparable ASES outcomes at 2 years, so the decision shifts to recovery speed and operative burden. The spacer wins on faster motion recovery and a roughly 27-minute shorter operation.
Think of the spacer mechanistically: it recenters the humeral head and offloads the acromiohumeral interface long enough to let the deltoid be retrained in a low-pain state. Because it resorbs by 12 months, durable benefit depends on the rehab it enables, not the balloon itself.
Patient selection matters. Series with low preoperative elevation and true pseudoparalysis had high failure and conversion to reverse TSA, so reserve the spacer for patients who still have functional forward elevation. Note the funding source (the device manufacturer) when weighting this evidence.